INSIGHTS ON CLINICAL TRIAL DESIGN

• The Flexibility Of Reconsent In Clinical Trials

  Explore the common misconceptions surrounding reconsent, as well as the reality of its ability to be a flexible, ethics-driven communication practice grounded in respect for participant autonomy.

• Operationalizing Immuno-Oncology Studies

  Managing CRS and immune risks demands early detection, rapid response, and skilled teams. Strong infrastructure and clear protocols enable safer immunotherapy trials beyond academic centers.

• BCVA, OCT, And IOP Testing In Clinical Trials

  Are minor inconsistencies in room setup and technician technique quietly compromising your study data? Learn how closing small operational gaps can prevent major downstream risks.

• Improving The eCOA Experience

  Discover how template-driven builds and reuse can slash eCOA timelines by 50% while solving the licensing and translation hurdles that delay First Patient In.

• Real-World Value Realized From DHTs In Clinical Trials

  10/22/2024

  Explore four real-world examples of clinical trials that successfully integrated DHTs. Each case study highlights how DHTs impacted specific aspects of trial design.

• How To Improve Patient ID And Retention In Chronic Disease Trials

  4/23/2026

  Leveraging primary care for chronic disease studies can accelerate patient identification, access to underrepresented populations, and improve retention rates.

• 4 Core Biomarker-Driven Study Designs In Oncology

  2/19/2026

  Modern oncology demands smarter trial designs. Explore how enrichment, stratification, and basket models transform biomarker data into successful, regulatory-ready clinical programs.

• Why Amendments Break Trials and How Elosity R3 Fixes It

  7/31/2026

  Protocol amendments are inevitable. The challenge is managing them without disrupting trial execution.

• Data Key In Addressing Patient Recruitment Challenges

  6/19/2025

  Explore how a Phase II trial for extensive-stage and previously treated small cell lung cancer overcame recruitment challenges with a data-driven solution designed to surface protocol-matched patients.